Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, provide their insights on the occurrence and management of the most common hematologic and nonhematologic adverse events associated with several PARP inhibitors that are used as maintenance therapy in ovarian cancer. Read More ›

Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, discuss the benefits and risks of using combination therapy with a PARP inhibitor and bevacizumab as first-line maintenance therapy in ovarian cancer. Read More ›

Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN and Ali McBride, PharmD, critically review the clinical trial data supporting the use of PARP inhibitors and bevacizumab as first-line maintenance therapy in ovarian cancer. Read More ›

Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN and Ali McBride, PharmD, describe their experiences in the use of niraparib, olaparib and nucaparib as first-line maintenance therapy in Ovarian Cancer. Read More ›

Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, discuss the relative benefits and risks of maintenance therapy in ovarian cancer with bevacizumab versus a PARP inhibitor. Read More ›

Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, deliberate on results from recent clinical trials showing the improvement in progression-free survival after first-line maintenance therapy with PARP inhibitors in patients with ovarian cancer, regardless of HRD status. The experts consider the impact of these data on providing improved treatment options for these patients. Read More ›

Amina Ahmed, MD, and Paula Anastasia, RN, MN, AOCN, debate the need for rebiopsy and retesting of molecular biomarkers in patients with HRD-discordant responses. The experts agree that reliability of the HRD “fingerprint” is dependent on the validity of the HRD test used as well as the ability to interpret results from these tests. Read More ›

Ali McBride, PharmD, and Paula Anastasia, RN, MN, AOCN, discuss how results from germline and somatic HRD testing help provide new options for patients with ovarian cancer. This approach has been a “game changer” in clinical outcomes for these patients. Read More ›

Amina Ahmed, MD, MS, Paula Anastasia, RN, MN, AOCN and Ali McBride, PharmD, MS, discuss the importance of genetic testing in the workup of patients with ovarian cancer, including both germline and somatic testing. The experts consider practice guidelines and results of recent clinical trials and their perspectives on the impact of genetic testing on treatment as well as clinical outcomes. Read More ›